» Articles » PMID: 19252018

Post-recurrence Survival in Completely Resected Stage I Non-small Cell Lung Cancer with Local Recurrence

Overview
Journal Thorax
Date 2009 Mar 3
PMID 19252018
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Resection is the best treatment for patients with stage I non-small cell lung cancer (NSCLC). Patterns of disease recurrence after complete resection in stage I NSCLC have not been well demonstrated. The aim of this study was to evaluate the prognostic predictors of post-recurrence survival in patients with resected stage I NSCLC with local recurrence.

Methods: The clinicopathological characteristics of 123 patients with local recurrence after complete resection of stage I NSCLC in Taipei Veterans General Hospital between 1980 and 2000 were retrospectively reviewed. Post-recurrence survival and their predictors were analysed.

Results: The patterns of local recurrence included local only in 74 (60.2%) and both local and distant in 49 (39.8%) patients. The 1 and 2 year post-recurrence survival rates for the 74 patients with local only recurrence were 48.7% and 17.6%, respectively. Tumour size (p = 0.033) and treatment for initial recurrence (p<0.001) were significant predictors for post-recurrence survival in 74 patients with local only recurrence in univariate analyses. The hazard of death was greater in patients with larger tumour size. Treatment for initial recurrence (p = 0.001) was still a significant prognostic indicator in multivariate analyses. Patients who underwent reoperation after local recurrence survived longer than those who received chemotherapy and/or radiotherapy and those that received no treatment.

Conclusions: Treatment for initial recurrence is a prognostic predictor for post-recurrence survival in resected stage I NSCLC with local recurrence. Complete surgical resection should be considered in selected candidates with resectable local recurrent disease.

Citing Articles

Efficacy of contrast versus non-contrast CT surveillance among patients surviving two years without recurrence after surgery for stage I lung cancer.

Jeon Y, Kang D, Lee J, Park S, Cho J, Choi Y Sci Rep. 2025; 15(1):6142.

PMID: 39979491 PMC: 11842762. DOI: 10.1038/s41598-025-90124-x.


Predicting Postoperative Lung Cancer Recurrence and Survival Using Cox Proportional Hazards Regression and Machine Learning.

Pu L, Dhupar R, Meng X Cancers (Basel). 2025; 17(1).

PMID: 39796664 PMC: 11719023. DOI: 10.3390/cancers17010033.


Multimodal deep learning radiomics model for predicting postoperative progression in solid stage I non-small cell lung cancer.

Kuang Q, Feng B, Xu K, Chen Y, Chen X, Duan X Cancer Imaging. 2024; 24(1):140.

PMID: 39420411 PMC: 11487701. DOI: 10.1186/s40644-024-00783-8.


The Interval of Computed Tomography Follow-Ups after Advanced Non-Small-Cell Lung Cancer Surgery Did Not Show Any Relationship with Survival.

Maru N, Hino H, Utsumi T, Matsui H, Taniguchi Y, Saito T Ann Thorac Cardiovasc Surg. 2024; 30(1).

PMID: 39370264 PMC: 11466525. DOI: 10.5761/atcs.oa.24-00093.


Long-term oncological outcomes of 3D versus 2D laparoscopic gastrectomy for gastric cancer: a randomized clinical trial.

Zhong Q, Chen J, Shang-Guan Z, Liu Z, Lin G, Wu D Gastric Cancer. 2024; 27(3):598-610.

PMID: 38379100 DOI: 10.1007/s10120-024-01470-0.